FDA
-
-
-
-
-
-
-
FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF
-
-
-
-
-
-
-
BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways
-
-
-
-
-
-
-
BioCardia Reports 2025 Business Highlights and Financial Results
-
-
-
-
-
-
-
BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA
-
-
-
-
-
-
-
BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial
-
-
-
-
-
-
-
BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter
-
-
-
-
-
-
-
BioCardia (BCDA) Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study
-
329,915 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

